Free press releases distribution network?

Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market - The company's pioneering Ectoin® product and production process uniquely position it for tremendous growth in the booming market for treatment of allergies - bitop.de
Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market

 

PRZOOM - /newswire/ - London, United Kingdom, 2013/06/20 - The company's pioneering Ectoin® product and production process uniquely position it for tremendous growth in the booming market for treatment of allergies - bitop.de.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent research on the extremolytes therapeutics market, Frost & Sullivan presents bitop AG with the 2013 European Frost & Sullivan Award for New Product Innovation. The company's path-breaking extremolyte platform enables a naturally-derived treatment for atopic dermatitis, allergic rhinitis and conjunctivitis, dry eye or dry nose syndrome, and respiratory diseases. The ready-to-adopt Ectoin®Allergy product line is expected to revolutionize how allergies are treated.

Ectoin® is one of the best studied natural extremolytes and occurs in different microorganisms. This natural compound helps extremophilic microorganisms to survive under harsh conditions. Ectoin® is produced within the cell, where it protects biomembranes, proteins, enzymes and nucleic acids against dehydration caused by high temperature, salt concentration, and low water content.

bitop AG introduced Ectoin® for human use to serve as a moisturizer and anti-aging element for dermatological applications. After many years of R&D and collaboration with research institutes, the compound has been validated for application as a naturally-derived ingredient to alleviate and treat e.g. allergic symptoms. In fact, the company recently filed for different patents with the United States Patent and Trademark Office (USPTO) to use Ectoin® in treating allergic rhinitis, asthma, COPD, atopic dermatitis, and in the prophylactic treatment of vascular leaks. In Europe, these patents have been granted by the European Patent Office.

Apart from its clinically-proven properties in dermatology and allergy treatments, Ectoin® can be used to treat nasal, mouth, and throat discomfort due to coughing or the common cold. It can also address dryness of the mucosa in the nose and of the conjunctiva in the eye in sicca syndromes due to its superior water-binding and membrane-stabilising features that enable rehydration and stabilisation of mucosal layers.

"With the World Allergy Organization (WAO) highlighting allergies as a global public health issue affecting approximately 30-40 percent of the population, especially children, bitop AG's breakthrough allergy products are uniquely positioned to address the needs of a burgeoning market," said Vin Nee, Frost & Sullivan Industry Analyst. "Importantly, the company's formulations are preservative-free, and clinically proven to be safe and reliable. Many Ectoin®-containing products have already received CE registration within the EU."

bitop AG is also the pioneer in the industrial bioprocessing of extremolytes. Its continuous production technique for Ectoin® uses Halomonas elongata (H. elongata) bacteria. The process avoids human errors or cross-contamination during the transfer of processing materials, which could occur in conventional bioreactor processing procedures.

"bitop AG's progressive efforts in the validation of Ectoin®-containing medical devices for treating allergic symptoms and the exploration in using Ectoin® in treating symptoms of different other diseases will continue to strengthen the company's product line," opined Vin Nee.

In recognition, Frost & Sullivan is pleased to present bitop AG with the 2013 European New Product Innovation Award in the extremolyte therapeutics market for allergies. Each year, Frost & Sullivan presents this award to the company that has developed an innovative element in a product by leverage leading-edge technologies. The award recognizes the value added features/benefits of the product and the increased ROI it offers customers, which in turn increases customer acquisition and overall market penetration potential.

Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About bitop AG
bitop AG (bitop.de), a German company founded in 1993, is focused on the development of Ectoin®-containing medical devices. Besides its Ectoin Allergy Products it is offering also other products such as nasal sprays for the symptomatic treatment of acute rhinosinusitis and rhinitis sicca, eye drops for the treatment of symptoms in case of dry eye syndrome or creams which alleviate symptoms in case of inflammatory skin diseases to distributors worldwide. bitop AG is worldwide the only manufacturer of Ectoin®.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organisation prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation

Contacts:
bitop AG
Dr. Silke Behne - Business Development Manager
T: +49(0)2302 91440-14 - E: behne[.]bitop.de.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Frost & Sullivan | bitop AG
Contact: Kristina Menzefricke - Frost.com 
+44(0)20 7915 7862 kristina.menzefricke[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  NAKIVO, Inc.

Visit  JobsWare.com

Visit  BizJobs.com







 
  ©2016 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today